Evan Dadosky’s Post

The healthcare sector continued to be a hub of private equity deal activity in 2023, relative to all PE deals across the world, despite higher global interest rates, inflationary pressures, and broader geopolitical uncertainty. Learn more in Bain & Company’s 2024 Global Healthcare Private Equity Report.

Stubborn inflation, high interest rates, geopolitical and economic uncertainty, and labor shortages exacted a toll on private equity markets in 2023, and healthcare private equity was not immune. Explore key insights on the industry and discover what lies ahead in the year to come in Bain & Company’s 2024 Global Healthcare Private Equity Report.

Stubborn inflation, high interest rates, geopolitical and economic uncertainty, and labor shortages exacted a toll on private equity markets in 2023, and healthcare private equity was not immune. Explore key insights on the industry and discover what lies ahead in the year to come in Bain & Company’s 2024 Global Healthcare Private Equity Report.

Stubborn inflation, high interest rates, geopolitical and economic uncertainty, and labor shortages exacted a toll on private equity markets in 2023, and healthcare private equity was not immune. Explore key insights on the industry and discover what lies ahead in the year to come in Bain & Company’s 2024 Global Healthcare Private Equity Report.

Stubborn inflation, high interest rates, geopolitical and economic uncertainty, and labor shortages exacted a toll on private equity markets in 2023, and healthcare private equity was not immune. Explore key insights on the industry and discover what lies ahead in the year to come in Bain & Company’s 2024 Global Healthcare Private Equity Report.

Stubborn inflation, high interest rates, geopolitical and economic uncertainty, and labor shortages exacted a toll on private equity markets in 2023, and healthcare private equity was not immune. Explore key insights on the industry and discover what lies ahead in the year to come in Bain & Company’s 2024 Global Healthcare Private Equity Report.

Stubborn inflation, high interest rates, geopolitical and economic uncertainty, and labor shortages exacted a toll on private equity markets in 2023, and healthcare private equity was not immune. Explore key insights on the industry and discover what lies ahead in the year to come in Bain & Company’s 2024 Global Healthcare Private Equity Report.

Stubborn inflation, high interest rates, geopolitical and economic uncertainty, and labor shortages exacted a toll on private equity markets in 2023, and healthcare private equity was not immune. Explore key insights on the industry and discover what lies ahead in the year to come in Bain & Company’s 2024 Global Healthcare Private Equity Report.

Stubborn inflation, high interest rates, geopolitical and economic uncertainty, and labor shortages exacted a toll on private equity markets in 2023, and healthcare private equity was not immune. Explore key insights on the industry and discover what lies ahead in the year to come in Bain & Company’s 2024 Global Healthcare Private Equity Report.

Stubborn inflation, high interest rates, geopolitical and economic uncertainty, and labor shortages exacted a toll on private equity markets in 2023, and healthcare private equity was not immune. Explore key insights on the industry and discover what lies ahead in the year to come in Bain & Company’s 2024 Global Healthcare Private Equity Report.